Bausch + Lomb CEO Saunders Shifts M&A Strategy After Xiidra Acquisition
Bausch + Lomb CEO Brent Saunders, known for his dealmaking reputation, has announced the acquisition of dry eye drug Xiidra from Novartis for $1.75 billion. With the transaction expected to close by the end of the year, Saunders plans to focus on integrating Xiidra into the company and will temporarily pause on pursuing larger mergers and acquisitions, while keeping an eye out for smaller deals.